Aligos Therapeutics Inc. (ALGS) stock
Price, quality score, analyst targets, a 30-day Kronos AI forecast and a Shariah screen for Aligos Therapeutics Inc., updated every trading day.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Price
$5.17
+9.07% today
Market cap
$30M
Overall quality
40/100
Kronos AI 30-day
+11.8%
8 of 8 simulated paths end higher
Aligos Therapeutics Inc. (ALGS) is a Health Care company in Biotechnology: Biological Products (No Diagnostic Substances), worth $30M. It trades at $5.17, up 9.07% today. Its overall quality score is 40 out of 100, ranked against the whole US market. 4 analysts' average target of $72.50 implies +1302.3% from today's price. Kronos AI's 30-day forecast is +11.8% (8 of 8 simulated paths end higher).
Open the full interactive analysis →Charts, technical signals, DCF fair value and ownership
Analyst price targets
| Average target | $72.50 |
| Low – high | $20.00 – $175.00 |
| Analysts | 4 |
| Upside to average | +1302.3% |
Kronos AI 30-day forecast
| Expected close | $5.30 (+11.8%) |
| Likely range | +7.5% … +16.2% |
| As of | 2026-10-27 |
8 of 8 simulated paths end higher.
Quality scores
| Profitability | 8 |
| Solvency | 55 |
| Growth | 58 |
| Overall | 40 |
| P/E | — |
Shariah screen
| Business activity | Passes |
| Debt and cash (AAOIFI 30%) | Not checked for this listing |
Automated screen of business activity and AAOIFI's 30% debt and cash limits. The 5% impermissible-income test is not applied. Check with a scholar before deciding.
Similar companies in Biotechnology: Biological Products (No Diagnostic Substances)
For information only, not investment advice. Prices updated: 2026-10-29.